Vaxess Technologies, Inc.
Vaxess is transforming healthcare by developing a proprietary transdermal patch and applicator capable of delivering a wide range of therapies and vaccines. Their vision is a needle-free, refrigeration-free future that enables self-administration of vaccines and therapeutics at home or in low-resource settings. The company integrates science from chemistry, biology, immunology, and engineering to create innovative healthcare solutions that are portable and accessible worldwide.
Industries
Nr. of Employees
medium (51-250)
Products
Sustained‑release transdermal microarray patch and applicator
A transdermal microarray patch system with dissolvable bioactive tips and a preloaded applicator that deposits slow‑release payloads into the dermal barrier for needle‑free, short‑wear‑time delivery of vaccines and therapeutics.
Formulation and drying platform for biologic stabilization
A matrix formulation and drying approach to stabilize vaccines, diagnostics reagents, and biospecimens for refrigeration‑free storage and transport.
Refrigeration‑free blood collection and stabilization device
A dried sample collection device and stabilization formulation intended to preserve blood analytes for field collection and shipment without refrigeration, compatible with downstream analytical workflows.
Sustained‑release transdermal microarray patch and applicator
A transdermal microarray patch system with dissolvable bioactive tips and a preloaded applicator that deposits slow‑release payloads into the dermal barrier for needle‑free, short‑wear‑time delivery of vaccines and therapeutics.
Formulation and drying platform for biologic stabilization
A matrix formulation and drying approach to stabilize vaccines, diagnostics reagents, and biospecimens for refrigeration‑free storage and transport.
Refrigeration‑free blood collection and stabilization device
A dried sample collection device and stabilization formulation intended to preserve blood analytes for field collection and shipment without refrigeration, compatible with downstream analytical workflows.
Services
Production of transdermal microarray patch systems under GMP conditions, including flexible array sizing and device assembly.
Co‑development partnerships with industry and academic groups to apply transdermal sustained‑release delivery and stabilization technologies across vaccine and therapeutic programs.
Production of transdermal microarray patch systems under GMP conditions, including flexible array sizing and device assembly.
Co‑development partnerships with industry and academic groups to apply transdermal sustained‑release delivery and stabilization technologies across vaccine and therapeutic programs.
Expertise Areas
- Transdermal and microneedle drug/vaccine delivery
- Biomaterials for biologic stabilization (silk fibroin)
- Vaccine and biologic thermostability and drying formulations
- Early‑phase clinical trial management
Key Technologies
- Transdermal microarray (microneedle) delivery
- Silk fibroin biomaterial-based formulations
- Sustained‑release drug delivery
- Formulation drying/stabilization for cold‑chain reduction
News & Updates
Vaxess announced the launch of a phase 1 trial for the H1 influenza vaccine delivered via Vaxess’s MIMIX™ patch, enrolling 45 healthy adult volunteers to evaluate safety, reactogenicity, tolerability, and immunogenicity profiles for two influenza vaccine dose levels.
Vaxess was awarded the 2023 Vaccine Innovation of the Year by Biotech Breakthrough Awards, recognizing their advancements in vaccine technology.
Vaxess was recognized in the 2023 Bostinno Fire Awards for their innovative contributions to healthcare.
A scientific article discussing how Vaxess’s silk microneedle platform enhances influenza vaccine responses.
A recent study published in PLOS ONE evaluating the safety and immune response of Vaxess’s H1 influenza vaccine patch.
Recognition for innovative vaccine technology by Biotech Breakthrough Awards.
Vaxess announced the launch of a phase 1 trial for the H1 influenza vaccine delivered via Vaxess’s MIMIX™ patch, enrolling 45 healthy adult volunteers to evaluate safety, reactogenicity, tolerability, and immunogenicity profiles for two influenza vaccine dose levels.
Vaxess was awarded the 2023 Vaccine Innovation of the Year by Biotech Breakthrough Awards, recognizing their advancements in vaccine technology.
Vaxess was recognized in the 2023 Bostinno Fire Awards for their innovative contributions to healthcare.
A scientific article discussing how Vaxess’s silk microneedle platform enhances influenza vaccine responses.
A recent study published in PLOS ONE evaluating the safety and immune response of Vaxess’s H1 influenza vaccine patch.
Recognition for innovative vaccine technology by Biotech Breakthrough Awards.